In an open-label, prospective, pharmacokinetic assessment, we evaluated total drug exposure (area under the curve [AUC]) of intravenous (IV) ganciclovir (GCV) and oral (p.o.) valganciclovir when normalized for body surface area (BSA) in pediatric liver (n 5 20) and renal (n 5 26) transplant patients Reference doses for IV GCV (200 mg/ m 2 ) and p.o. valganciclovir (520 mg/m 2 ) were based on adult doses, and adjusted for BSA initially, and BSA and renal function (estimated via creatinine clearance [CrCL]) thereafter. Renal transplant patients received GCVon days 1^2, valganciclovir 260 mg/m 2 on day 3, and valganciclovir 520 mg/m 2 on day 4. Liver transplant patients received twice daily GCV from enrollment to day 12, and then valganciclovir twice daily on days 13^14. GCV pharmacokinetics were described using a population pharmacokinetic approach. Type of solid organ transplant (kidney or liver) had no effect on GCV pharmacokinetics. Median GCV exposure following valganciclovir 520 mg/m 2 was similar to that with IV GCV, and to that reported in adults. Patients o5 years of age had AUC values approximately 50% of those compared with older age ranges; dosing based on both BSA and CrCL increased drug exposure in younger patients. A dosing algorithm based on BSA and CrCL should be tested in future studies.
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Cytomegalovirus (CMV) is a major cause of morbidity and mortality in children after solid organ transplantation (SOT) (1) , because many of them are likely to be CMV seronegative at the time of transplantation.While the ef¢cacy of ganciclovir (GCV) for the prevention and treatment of CMV in SOT recipients is well established in adults (2^4), its use in the management of CMV disease is limited by poor oral (p.o.) bioavailability (5) , and thus the need for long-term intravenous (IV) administration.
Valganciclovir, the valine ester of GCV, overcomes the limitations of p.o. GCV and is a convenient alternative to IVadministration. The 10 -fold higher absolute bioavailability of p.o. valganciclovir compared with GCV (5, 6) , means that, in adults, dosing with p.o. valganciclovir 900 mg once daily provides similar GCV exposure to IV GCV (5 mg/kg/ day) (7 ) . However, dosing with valganciclovir tablets may not be appropriate in some patients because of their inability to swallow solids for a variety of reasons. To this end, a p.o. valganciclovir solution has been developed to accommodate these patients that is bioequivalent to the tablet formulation and with a similar safety pro¢le, thus allowing the 2 p.o. formulations to be interchangeable (8) .
No universal rule exists for converting adult drug doses to doses for children (9) . Adjusting according to body weight or body surface area (BSA) is not always successful (10, 11) . Furthermore, a p.o. solution of valganciclovir would also be useful for children unable to swallow tablets or capsules. To ¢ll in this knowledge gap, we designed and conducted 2 independent studies of p.o. valganciclovir solution and IV GCV in de novo pediatric kidney or liver transplant recipients. We hypothesized that IV dosing of GCVand p.o. dosing of valganciclovir, normalized for BSA in pediatric liver and kidney transplant patients, would provide similar GCVarea under the curve (AUC) values as those established for adults. Additionally, we hypothesized that BSA-normalized p.o. valganciclovir doses would provided comparable GCV AUC values to BSA-normalized IV GCV doses in this population.
Methods

Study design and patient population
Two open-label studies were conducted in 9 US centers (6 renal and 3 liver). Both studies were approved by the Institutional Review Boards at each institution and written informed consent was provided by patients' parents or guardians and assent by the children as appropriate.
Renal study
Children aged 3 months to 16 years considered at risk of developing CMV disease who had received their ¢rst kidneyonly transplant were eligible for study entry. Patients were required to have absolute neutrophil count 41000 cells/mL; platelet count 425,000 cells/mL; hemoglobin 48.0 g/dL; and stable renal function with creatinine clearance (CrCL) 445 mL/min/1.73 m 2 (Schwartz et al. formula [12] ). Exclusion criteria included allergic or other significant adverse reaction to acyclovir, GCV, or valacyclovir; severe, uncontrolled diarrhea or evidence of malabsorption; patients simultaneously participating in another trial, except as approved by the sponsor; female patients who were lactating and would not discontinue nursing before study entry; pregnancy; and liver function impairment of 45 times the upper limit of normal for aspartate aminotransferase (AST) or alanine aminotransferase (ALT).
Liver study
The criteria for the liver trial were identical to those of the renal study, with the exception that children at risk of contracting Epstein^Barr virus (EBV) could also be included. Exclusion criteria were also identical, except for the exclusion of liver function impairment and the inclusion of evidence of graft rejection or antiviral prophylaxis with a treatment other than IV GCV between transplant and enrollment. 
Calculation of dosage
According to renal function
In both studies, the reference doses for both agents were adjusted for reduced renal function based on estimated CrCL, as outlined in Table 1 . CrCL was estimated from serum creatinine using the Schwartz et al. formula (12) :
where k 5 0.45 for those aged o2 years, k 5 0.55 for those aged ! 2 years to o13 years, and for those aged ! 13 years to 20 years, k 5 0.7 for males and k 5 0.55 for females.
Drug regimens and procedures
Renal study
Individual study drug dosing lasted for a total of 4 days. The shorter interval in the renal study compared with the 14 days in the liver study, resulted from the more rapid time to stability and discharge from the hospital for the renal transplant patients. Screening assessments were performed in the ¢rst week after transplantation after the stabilization of renal function, followed by 4 consecutive days of treatment with study drugs, a follow-up visit (day of last pharmacokinetic sample, 28^32 days post transplant), and a safety review visit (28 days after cessation of study drug AE 4 days). Serum creatinine used to estimate CrCL was measured on each day of treatment and at the follow-up visit. After stabilization of renal function following transplantation, subjects received treatment once daily between 7 and 9 a.m. with a single dose of IV GCVon days 1 and 2 and a single dose of p.o. valganciclovir solution of 260 mg/ m 2 on day 3 and 520 mg/m 2 on day 4. Blood samples for determination of GCV concentrations were collected on dosing-days 2, 3, and 4 as follows: pre-dose (up to 2 h before dosing), and 1 h (immediately before the end of the infusion), and between 2^3, 5^7, and 10^12 h post dose on day 2; pre-dose, and between 0.25^0.75, 1^3, 5^7, and 10^12 h post dose on day 3; and pre-dose, and between 0.25^0.75, 1^3, 5^7, 10^12, and 22^24 h post dose on day 4.
Liver study
Screening and enrollment were conducted between days 1 and 4 (day 0 was the day of the transplant); patients received study drugs from enrollment up to day14 post transplant.The follow-up and safety reviews were on days 28^32 and 42 AE 4 post treatment, respectively. Serum creatinine used to estimate CrCL was measured on days 11^14. Study drugs were administered twice daily^between 7 and 9 a.m. for the ¢rst dose, and the second as close as possible to 12 h after the ¢rst dose. However, the AUC was calculated using only samples obtained during the 12-h period around the morning dose of drug.The 24 -h AUC was calculated using non-linear mixed e¡ect modeling (NONMEM) assuming once a day dosing.
Patients received treatment with IV GCV, initiated on enrollment (days 1^4 after transplantation) and continued to day 12 post transplant. On days 13 and 14 post transplant, patients received p.o. valganciclovir solution twice daily. Blood sampling was conducted on days 12 and 14 as follows: pre-dose (up to 2 h before dosing), and 1 h (immediately before the end of the infusion), and between 2^3, 5^7, and 10^12 h post dose on day 12; and pre-dose, and between 0.25^0.75, 1^3, 5^7, and 10^12 h post dose on day 14.
Drug administration
In both studies, IV GCV was given over 1 h as a constant rate infusion. GCV for IV infusion (Cytovene s , Roche, Nutley, New Jersey, USA) was provided as sterile, lyophilized powder in sealed vials containing 500 mg GCV for reconstitution in 10 mL of saline.Valganciclovir was provided as a strawberry£avored 15 g powder blend containing 3 g valganciclovir; it was reconstituted with 50 mL water to give a ¢nal volume of 60 mL; the solution was sweetened with saccharine and was administered within 15 min of a meal. One batch of valganciclovir p.o. solution was used in each study.
Study assessments and procedures
Screening assessment in both studies included a limited physical examination, laboratory safety tests (hematology, serum chemistry), and a medical examination including assessment of concomitant illnesses, laboratory safety tests, assessment of puberty stage (Tanner stage [14] ), pregnancy tests for females of child-bearing potential, measurement of serum creatinine, and estimated CrCL. In addition, the CMV serological status of the graft and recipient was determined in the renal study, and the CMVand EBV serological status of the graft and recipient was determined in the liver study.
Adverse events occurring since consent and medications to treat these adverse events were also recorded in both studies.
Drug assay
In each study, venous blood (1 mL) was collected into plastic ethylene diamine tetraacetic acid tubes and centrifuged (15 min at 1200 Âg) at 41C within 30 min. Plasma samples were frozen immediately at À 701C pending analysis. The plasma concentration of GCV was determined byAnalytico Medinet (Breda, the Netherlands) following deproteination, by adding trichloroacetic acid, using a validated speci¢c liquid chromatography-tandem mass spectrometry method. GCV was provided by Ho¡mann La-Roche (Basel, Switzerland). The dynamic range for the quanti¢cation of GCV was between 0.040 and 20 mg/mL, which was based on 8 different concentration levels (coef¢cient of correlation ! 0.99. The overall accuracy and inter-assay variability of the assay was 98.7^105% and 0.7^12.0%, respectively.
Because of the rapid conversion of valganciclovir to GCV, plasma valganciclovir concentrations are not detectable, and were therefore not measured in either study or included in the pharmacokinetic model.
Population pharmacokinetic modeling
Pharmacokinetic model
A 2-compartmental model for GCV was considered appropriate based on previous population pharmacokinetic analyses for GCV in adult SOT recipients (7 ) . The model parameters were clearance (CL), volume of distribution at steady state (V ss ), intercompartmental clearance (Q), peripheral volume of distribution (V periph ), ¢rst-order absorption (for valganciclovir), lag time, and bioavailability of GCV from valganciclovir (F1). NONMEM software (Version V, Icon, Dublin, Ireland) and the ¢rst-order estimation method were used. NONMEM was developed at the University of California, San Francisco as software for ¢tting non-linear mixed effects (statistical regression-type) models. The methodology is particularly useful for population pharmacokinetic analyses and in situations such as in this trial, where there are few pharmacokinetic samples per subject. Inter-subject variability was assessed using an exponential function. A combined multiplicative and additive error model was used for the residual random effects.
Covariate selection was conducted on gender, age, height, puberty, body weight, BSA, type of SOT (kidney or liver), serum creatinine, AST, ALT, total bilirubin, and CrCL derived from the Cockroft^Gault formula (CrCLC) (15) and Schwartz et al. formula (CrCLS) (11) . Stepwise generalized additive modeling in Xpose 3.102 was used initially to select the covariates to be tested within NONMEM. Then a comprehensive forward addition and backward procedure was followed to build the ¢nal covariate model. Model discrimination was based on a decrease in objective function values and visual inspection of goodness-of-¢t plots.
Pharmacokinetic endpoints
The primary pharmacokinetic parameter in both studies was the extent of exposure (AUC) to GCVafter administration of IV GCVand p.o. valganciclovir solution, determined as the area under the GCV concentration^time curve over 24 h (AUC 0 À 24 ) using population pharmacokinetic analysis. Population pharmacokinetic analysis was also used to determine secondary pharmacokinetic parameters, which included CL; F1;V ss ;V periph ; volume of central compartment (V cent ); absorption rate constant (K a ); maximum plasma concentration (C max ); and terminal elimination half-life (t 1/2 ). Individual parameters were calculated using individual post hoc estimates derived from population estimates and the individual data.
Statistics
No formal statistical tests or sample size calculations were performed.The planned target recruitment was 24 patients in the renal study and 20 patients in the liver study. These sample sizes were deemed adequate to derive the pharmacokinetic pro¢le of GCV after administration of IV GCV and p.o. valganciclovir solution. Descriptive statistics were used to summarize the pharmacokinetic data.
Results
Renal study
Twenty-six patients were enrolled, aged 5 years (n 5 5), 6^11 years (n 5 7), and 12^16 years (n 5 14) ( Table 2) . One patient withdrew prematurely after refusing treatment with valganciclovir p.o. solution, having received both doses of IV GCV. Data for this patient are included in all but the pharmacokinetic analyses. Two patients had their dose of study medication reduced because of poor renal function. The ¢rst patient (13 years old) received 25% of 
EBV status, n (%) 
Liver study
In the liver study, 20 patients were enrolled: aged 5 years (n 5 15), 6^11 years (n 5 2), and 12^16 years (n 5 3) ( Table  2) . One patient with renal function slightly outside of the 45 mL/min/1.73/m 2 inclusion criteria (CrCL 5 41.7 mL/ min/1.73 m 2 ) was inadvertently entered into the study; the subject's data were included in the analyses. Fifteen patients completed the study. Five of the 20 patients (all aged o5 years) were withdrawn.
Pharmacokinetic results
Final pharmacokinetic model (combined patient cohort)
Of the 46 patients enrolled, 43 were included in the pharmacokinetic model. One patient from the renal study was excluded from the pharmacokinetic model because plasma levels were not recorded. Two patients from the liver study were withdrawn before receiving study drug and were also excluded from the pharmacokinetic model. Three other liver transplant subjects did not complete the entire study but had suf¢cient data to include in the pharmacokinetic analysis. Of the 43 patients included in the model, data were included from a liver transplant recipient for whom GCV plasma concentrations only after administration of IV GCV were available because this patient was withdrawn before p.o. valganciclovir administration, and from another liver transplant recipient who received p.o. valganciclovir for only1 day.
The ¢nal model for GCV plasma concentrations was a 2-compartmental model with ¢rst-order formation for p.o. valganciclovir, lag time, and relative bioavailability. Intersubject random variability was modeled for K a , CL,V ss , Q, and F1 as exponential errors. The residual error consisted of a multiplicative and an additive error arm. The multiplicative error was 29% and the additive error was 0.14 ng/ mL, which is about 3 -fold above the lower limit of quanti¢-cation (0.04 ng/mL). The population pharmacokinetic parameters of the ¢nal model are presented in Table 3 . The height of the patient and CrCLC were identi¢ed as statistically significant covariates for CL, V ss , and V periph . Neither age, gender, nor type of organ were significant covariates in this model. Inspection of the goodness-of-¢t plots did not show any substantial bias thus indicating that the pharmacokinetic parameters were well estimated. There was no clinically relevant difference in covariate selection between using the Schwartz and Cockcroft Gault formulae for calculation of CrCL (Roche data on ¢le).
Individual pharmacokinetic parameters
Summaries of the derived and individual estimated parameters from both studies are shown inTables 4 and 5, respectively. AUC 0 À 24 and C max were calculated for the doses of 200 mg/m 2 for IV GCV and 520 mg/m 2 for p.o. valganciclovir solution. Two subjects had their doses decreased per the dosing algorithm (Table 1) Across both studies, exposure to GCV was noticeably low in very young patients (aged 5 years) for both IV GCV and the p.o. valganciclovir solution (Table 4 ). In addition, in all age groups, exposure to GCV following treatment with IV GCV was broadly similar to that following treatment with p.o. valganciclovir solution 520 mg/m 2 . In both liver and kidney, C max values for all ages were comparable, with means ranging 9.03^12.2 C max . Values were notably lower for p.o. valganciclovir, but also comparable between age groups/transplant types with means of 5.10^6.9. In the renal study, CL increased with age, as did drug exposure. Moreover, GCVexposure based on BSA alone in the renal study was generally lower in younger children, but was increased when corrected for both BSA and renal function (Fig. 1) . The very low r value, when adjusting by both BSA and CrCl, indicates that AUC is no longer correlated with age, an important improvement in a dosing regimen. In contrast, in the liver study, there was no clear pattern in the age-related effect on clearance or exposure of GCV. This could be, in part, attributed to the skewed distribution of patients across the age groups in the liver study. In this study, the clearance of GCV was markedly lower in the 13 children aged 5 years than the 3 children aged 12^16 years; however, it was lower still in the 2 children aged 6^11 years ( Table 5 ). The t 1/2 was shorter in younger children (median 1.65 h) than in those aged 6^11 and 12^16 years (6.80 and 4.35 h, respectively). Similarly, in the renal study, t 1/2 increased with increasing age; median values were 3.28 (range 1.97^6.31), 4.41 (range 3.06^12.77 ), and 5.62 (3.32^27.04) in the 0^5, 6^11, and 12^16 years age groups, respectively.
The estimated bioavailability of GCV from p.o. valganciclovir solution was only slightly lower in the younger children than the older children in both studies (Table 5) ; this suggests that there was essentially no dependence of F1 values on age.
Safety
In both studies, IV GCV and valganciclovir p.o. solution were generally well tolerated. The majority of treatmentemergent adverse events were of mild or moderate severity and were gastrointestinal in nature. There were no deaths in either study.
Renal study
Treatment-emergent adverse events were reported in 50% of patients in the IV GCV phase and in 32% of patients in the p.o. valganciclovir phase. Four patients experienced treatment-related adverse events; 3 while receiving p.o. valganciclovir solution (nausea n 5 1, vomiting n 5 1, and headache n 5 2), and 1 while receiving IV GCV (thrombocytopenia). Four severe adverse events were reported, of which 1 occurred on treatment (sepsis; with valganciclovir solution). Four patients experienced 6 serious adverse events, of which 2 occurred on treatment with p.o. valganciclovir but were not considered treatment related.
Liver study
Treatment-emergent adverse events were reported in 90% of patients in the IV GCV phase of the study. There were only 2 adverse events in the p.o. valganciclovir treatment phase, which were not severe, serious, or treatment related. Three patients experienced a total of 6 adverse events that were remotely or possibly related to treatment with IV GCV (rash in 1 patient, anemia and renal impairment in 1 patient, and vomiting, diarrhea, and increased hepatic enzymes in 1 patient). Of 22 severe adverse events, 2 were life threatening (2 occurrences of post-procedural hemorrhage in 1 patient during IV GCV treatment and during the o¡-treatment phase of the study). Ten patients experienced 14 serious adverse events in the IV GCV phase, of which 2 were related to study treatment (vomiting and increased hepatic enzymes).
Discussion
The median exposure to GCV in older children receiving 520 mg/m that observed in adult patients receiving 900 mg valganciclovir once daily (mean of approximately 46 mg Á h/ mL) (5, 7 ). In the renal study, the GCV exposure, based on BSA alone, was generally low in younger children; drug exposure was increased in this age group when corrected for both BSA and renal function (estimated via CrCL). The clear trend of decreasing exposure with younger age shown in the renal study was not observed in the liver study, presumably because there were limited number of patients in the 2 older liver transplant groups. The youngest children were underexposed to GCV by about 2-fold; this did not appear to be attributable to a lack of simultaneous adjustment for age in clearance because clearance of GCV was lower in the youngest age groups compared with the oldest age groups (median 4.7 L/h in 0^5 -year-olds vs. 7.4 L/h in 121 6 -year-olds in the renal study and 15.1 vs. 4.1 L/h in the liver study). These results suggest that a dosing algorithm based on BSA alone is inadequate to deliver similar GCV exposures across the age ranges investigated in these 2 pediatric studies.
Because the bioavailability of GCV from p.o. valganciclovir solution was essentially independent of age and the drug is eliminated almost exclusively unchanged in the urine, we propose that renal function (assessed via CrCLS) should be included as a standard criterion in addition to BSA in future dosing algorithms for p.o. valganciclovir in children. Estimated CrCL has been used previously as a predictor of systemic GCV clearance in a dosing algorithm in a population pharmacokinetic model in adult SOT recipients (7) . An individualized dosing algorithm for p.o. valganciclovir solution or tablets (where dose 5 7 Â BSA Â CrCL) has recently been shown in a pediatric population to provide GCV exposures similar to those obtained in adults, with age and type of SOT having limited impact on GCV pharmacokinetics. The dosing schedule used in this report was based on the data presented in this paper (16) .
In our studies, the bioavailability and C max of GCV from p.o. valganciclovir solution was similar to that previously obtained in adult SOT recipients (44^71% [both studies] vs. 61% (17 ) and 5^7 mg/L [renal study] vs. 5^6 mg/L (5), respectively). Previous data have shown that the pharmacokinetics of GCV are generally similar between neonates, children, and adults (18^21).
Given the short duration of these studies, and the extensive use of concomitant medications, it is dif¢cult to assess causality or draw conclusions regarding the overall safety pro¢le.
Significant £uid shifts and ascitic £uid losses can occur in the ¢rst 2 weeks after liver transplantation, and could have potentially in£uenced GCV clearance values in the liver study. However, in our model, the type of SOT was not found to be a significant covariate for clearance of the drug.
The dosage was adjusted for reduced renal function based on estimated CrCL calculated using the Schwartz et al. formula (CrCLS) (12) . The Schwartz et al. formula may overestimate glomerular ¢ltration rate (GFR) in the pediatric population, particularly at GFR levels o60 mL/ min/1.73 m 2 (22) . Nevertheless, CrCLS has good negative predictive value when CrCLS is 420 mL/min/1.73 m 2 (i.e., when CrCLS is 420 mL/min/1.73 m 2 there is a 95% chance that GFR measured by iothalamate clearance is 415 mL/ min/1.73 m 2 ) (22) . As a baseline CrCL of 445 mL/min/ 1.73 m 2 was required for enrollment, overestimation of GFR with the Schwartz formula may be less of a concern (provided renal function remained stable during the study period).
The systemic exposure to GCV in pediatric renal or liver transplant recipients was similar after administration of p.o. valganciclovir solution (520 mg/m 2 ) or IV GCV (200 mg/ m 2 ). As a dosing algorithm based only on BSA resulted in under-exposure of younger children, an algorithm including individually estimated CrCL and BSA (dose 5 7 Â BSA Â CrCL) is currently being investigated and should provide adequate GCVexposure in pediatric renal or liver transplant recipients for the prevention of CMVdisease.
